<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26557">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01667315</url>
  </required_header>
  <id_info>
    <org_study_id>Bupivacaine 0,375%</org_study_id>
    <nct_id>NCT01667315</nct_id>
  </id_info>
  <brief_title>Minimum Effective Volume of 0.375% Bupivacaine in Interscalene Brachial Plexus Block</brief_title>
  <official_title>Minimum Effective Volume of 0.375% Bupivacaine in Ultrasound- and Nerve Stimulator-guided Interscalene Brachial Plexus Block for Shoulder Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <authority>Brazil: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of ultrasound in regional anesthesia enables reduction in the local anesthetic
      volume. The present study aimed to determine the minimum effective volume of 0.375%
      bupivacaine with epinephrine for interscalene brachial plexus block for shoulder surgery.
      Following approval by the Research Ethics Committee, patients with a physical condition of I
      or II according to the American Society of Anesthesiologists, between 21 and 65 years old
      and subjected to elective surgery of the shoulder and interscalene brachial plexus block
      will be recruited. The volume of the anesthetic will be determined using a step-up/step-down
      method and based on the outcome of the preceding block. Positive or negative block results
      in a 1mL reduction or increase in volume, respectively. The success of the block is defined
      as the presence of motor block in two muscle groups and the absence of thermal and pain
      sensations in the necessary dermatomes within 30 minutes of the injection. Diaphragmatic
      paralysis, pulmonary function and analgesia will be quantified at 30 minutes, 4 and 6 hours.
      Data will undergo statistical analysis in order to determine minimum effective volume of
      0.375% bupivacaine and, secondarily, the maximum volume that maintains the diaphragmatic
      function, evaluate diaphragm paralysis and its influence in pulmonary function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Minimum effective volume of 0,375% bupivacaine</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Minimum effective volume of 0,375% bupivacaine with epinephrine in ultrasound-guided interscalene brachial plexus block for shoulder surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum 0,375% bupivacaine volume that maintains the diaphragmatic function</measure>
    <time_frame>Before block, 10, 20 and 30 minutes, 4 and 6 hours after</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum effective volume of 0,375% bupivacaine with epinephrine in ultrasound-guided interscalene brachial plexus block for shoulder surgery without diaphragmatic block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>Before block, 30 minutes, 4 and 6 hours after</time_frame>
    <safety_issue>No</safety_issue>
    <description>Spirometric evaluation of forced vital capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diaphragmatic Function</measure>
    <time_frame>Before block, 30 minutes, 4 and 6 hours after</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diaphragmatic movement on ultrasound</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Shoulder Surgery</condition>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivacaine 0,375%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine 0,375%</intervention_name>
    <description>Positive or negative block results in a 1-mL reduction or increase in volume, respectively.</description>
    <arm_group_label>Bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 21 and 65 years

          -  Candidates for an elective surgical intervention on the shoulder with indication for
             anesthesia via brachial plexus block

          -  Physical condition of I or II according to the American Society of Anesthesiologists

          -  Body mass index up to 35 kg.m-2

        Exclusion Criteria:

          -  Chronic obstructive pulmonary disease

          -  Cognitive impairment or active psychiatric condition

          -  Infection at the site of the puncture for the block

          -  Coagulopathy

          -  Bupivacaine allergy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Federal University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04024-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luiz Fernando Saldanha de Almeida, MD</last_name>
      <email>luizfsa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Marcelo Vaz Perez, MD PhD</last_name>
      <email>marcelovazperez@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marcelo V Perez, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 16, 2012</lastchanged_date>
  <firstreceived_date>August 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Luiz Fernando Saldanha de Almeida</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
